**below information comes from website and for reference only**
According to medical professionals, CBD inhalers are the preferred delivery application for patients currently receiving CBD oil for certain diseases.CBD inhalers use 99.99% Hfa-134A For Pharm Grade as propellant.
On average, inhaled CBD is delivered to the blood almost immediately and reaches maximum blood concentrations within about 10 minutes, compared to 1-4 hours for oral CBD.The proportion of CBD absorbed by patients or bioavailability of inhalation CBD was about 45%, compared with 15% for oral CBD. This means that the patient needs a lower dose, which increases the dose per unit volume. Pharmaceutical Aerosols HFA-134A Medication is used as propellant and safe.
Another warning for increased support for inhalers is to reduce the incidence of side effects, including digestive problems associated with long-term intake of synthetic compounds.
In addition, Impression said, it is based on "existing preliminary but promising research institutions" that have shown that CBD's powerful anti-inflammatory properties can be used to treat inflammation in the lungs and to transport CBD to the affected area using inhalation devices. Pharmaceutical product HFA-134A (P) is necessary for the inhaler.
IHL also says it has identified preclinical and pre-human studies that broadly support the potential of CBD to treat inflammation associated with pneumonia and acute lung injury experienced in patients with asthma and chronic obstructive pulmonary disease (COPD).
Impression also believes that its CBD treatment could be used to help with the ongoing COVID-19 pandemic.
"It is clear that some COVID-19 patients develop pneumonia and acute lung damage through inflammatory processes, so Impression's Medical Advisory Board will investigate the potential of CBD inhalers to help recover from these diseases," the company said. "
More than 2.5 million Australians suffer from mild to severe asthma, and the country has recently reported a shortage of Ventura.
Joel Latham, Managing Director of Impression, said: "We expect CBD inhalers to be the preferred mode of delivery for many patients and we are excited about the prospect of opening up new unregistered treatments for patients with lung inflammation-related conditions. "